A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Citations Over TimeTop 10% of 2013 papers

Abstract

Treating patients with novel biological agents is becoming a leading trend in oncology. Unlike cytotoxic agents, for which efficacy and toxicity monotonically increase with dose, biological agents may exhibit non-monotonic patterns in their dose-response relationships. Using a trial with two biological agents as an example, we propose a dose-finding design to identify the biologically optimal dose combination (BODC), which is defined as the dose combination of the two agents with the highest efficacy and tolerable toxicity. A change-point model is used to reflect the fact that the dose-toxicity surface of the combinational agents may plateau at higher dose levels, and a flexible logistic model is proposed to accommodate the possible non-monotonic pattern for the dose-efficacy relationship. During the trial, we continuously update the posterior estimates of toxicity and efficacy and assign patients to the most appropriate dose combination. We propose a novel dose-finding algorithm to encourage sufficient exploration of untried dose combinations in the two-dimensional space. Extensive simulation studies show that the proposed design has desirable operating characteristics in identifying the BODC under various patterns of dose-toxicity and dose-efficacy relationships.

Related Papers

• → The Total i3+3 (Ti3+3) Design for Assessing Multiple Types and Grades of Toxicity in Phase I Trials(2022)2 cited
• → Including Information on the Therapeutic Window in Bioequivalence Acceptance(2008)3 cited
• → An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy(2018)1 cited
• → The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide(1988)8 cited
• Optimal biological dose can be a valid surrogate for maximum tolerated dose in Phase 1 clinical evaluations of targeted anticancer agents.(2007)